Description:

MYGN is the ticker symbol for Myriad Genetics, Inc., a biotechnology company listed on the New York Stock Exchange (NYSE). Myriad Genetics specializes in molecular diagnostic testing and personalized medicine, leveraging its expertise in genetics to develop tests that can predict, diagnose, and manage disease. The company's portfolio includes tests for hereditary cancers, such as breast and ovarian cancer, as well as other genetic conditions. Through its research and development efforts, Myriad aims to improve patient outcomes by providing actionable information to healthcare providers and patients.

Data:

Yields: